Brokerages Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) Price Target at $39.89

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the twelve analysts that are presently covering the stock, MarketBeat reports. Six investment analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $39.89.

Several equities research analysts have recently issued reports on the stock. Wells Fargo & Company lowered shares of Kymera Therapeutics from an "overweight" rating to an "equal weight" rating and set a $26.00 price target for the company. in a research note on Tuesday, December 19th. Piper Sandler lifted their price objective on shares of Kymera Therapeutics from $39.00 to $56.00 and gave the company an "overweight" rating in a research note on Tuesday, February 27th. JPMorgan Chase & Co. lifted their price objective on shares of Kymera Therapeutics from $34.00 to $47.00 and gave the company an "overweight" rating in a research note on Friday, February 23rd. Wolfe Research initiated coverage on shares of Kymera Therapeutics in a research note on Thursday, February 15th. They issued a "peer perform" rating for the company. Finally, Stifel Nicolaus lifted their price objective on shares of Kymera Therapeutics from $35.00 to $55.00 and gave the company a "buy" rating in a research note on Friday, February 23rd.

Kymera Therapeutics Trading Up 0.1 %

Shares of KYMR stock traded up $0.03 during trading hours on Friday, hitting $40.20. 544,045 shares of the company were exchanged, compared to its average volume of 720,499. The firm has a fifty day simple moving average of $37.91 and a 200 day simple moving average of $25.74. Kymera Therapeutics has a 52-week low of $9.60 and a 52-week high of $45.31.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its quarterly earnings results on Thursday, February 22nd. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.19. Kymera Therapeutics had a negative net margin of 187.00% and a negative return on equity of 34.83%. The company had revenue of $47.90 million during the quarter, compared to analyst estimates of $41.94 million. During the same quarter last year, the business posted ($0.60) EPS. Kymera Therapeutics's quarterly revenue was up 197.5% compared to the same quarter last year. Sell-side analysts anticipate that Kymera Therapeutics will post -3.16 earnings per share for the current year.

Insider Buying and Selling at Kymera Therapeutics

In other news, insider Ellen Chiniara sold 3,295 shares of Kymera Therapeutics stock in a transaction on Thursday, January 4th. The shares were sold at an average price of $22.58, for a total transaction of $74,401.10. Following the completion of the sale, the insider now directly owns 34,205 shares of the company's stock, valued at approximately $772,348.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, insider Ellen Chiniara sold 3,295 shares of Kymera Therapeutics stock in a transaction on Thursday, January 4th. The shares were sold at an average price of $22.58, for a total transaction of $74,401.10. Following the completion of the sale, the insider now directly owns 34,205 shares of the company's stock, valued at approximately $772,348.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jeffrey W. Albers sold 10,000 shares of Kymera Therapeutics stock in a transaction on Tuesday, January 23rd. The stock was sold at an average price of $30.05, for a total transaction of $300,500.00. The disclosure for this sale can be found here. Insiders sold a total of 487,346 shares of company stock valued at $19,999,112 in the last three months. Company insiders own 16.67% of the company's stock.

Institutional Trading of Kymera Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Amundi purchased a new position in shares of Kymera Therapeutics in the fourth quarter valued at about $49,000. Point72 Hong Kong Ltd bought a new position in shares of Kymera Therapeutics during the first quarter valued at about $53,000. Advisors Asset Management Inc. bought a new position in shares of Kymera Therapeutics during the fourth quarter valued at about $58,000. Royal Bank of Canada raised its stake in shares of Kymera Therapeutics by 30.0% during the second quarter. Royal Bank of Canada now owns 2,773 shares of the company's stock valued at $64,000 after acquiring an additional 640 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in shares of Kymera Therapeutics by 65.4% during the second quarter. Tower Research Capital LLC TRC now owns 2,899 shares of the company's stock valued at $67,000 after acquiring an additional 1,146 shares during the last quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.